Research graph
References from Integration of microphysiological systems with computational and digital twin modeling for pharmaceutical development: a systematic review. Local targets link to admitted publications; unresolved targets remain external evidence.
Diagnosing the decline in pharmaceutical R&D efficiency
10.1038/nrd3681 · 2012 · External reference
Can the pharmaceutical industry reduce attrition rates?
10.1038/nrd1470 · 2004 · External reference
Clinical development success rates for investigational drugs
10.1038/nbt.2786 · 2014 · External reference
Estimation of clinical trial success rates and related parameters
10.1093/biostatistics/kxx069 · 2018 · External reference
Trends in clinical success rates and therapeutic focus
10.1038/d41573-019-00074-z · 2019 · External reference
Phase II and phase III failures: 2013–2015
10.1038/nrd.2016.184 · 2016 · External reference
Phase II and phase III attrition rates 2011-2012
10.1038/nrd4090 · 2013 · External reference
Innovation in the pharmaceutical industry: new estimates of R&D costs
10.1016/j.jhealeco.2016.01.012 · 2016 · External reference
Estimated research and development investment needed to bring a new medicine to market, 2009-2018
10.1001/jama.2020.1166 · 2020 · External reference
How to improve R&D productivity: the pharmaceutical industry's grand challenge
10.1038/nrd3078 · 2010 · External reference
Performance assessment and economic analysis of a human liver-chip for predictive toxicology
10.1038/s43856-022-00209-1 · 2022 · External reference
Comparison of treatment effects between animal experiments and clinical trials: systematic review
10.1136/bmj.39048.407928 · 2007 · External reference
Can animal models of disease reliably inform human studies?
10.1371/journal.pmed.1000245 · 2010 · External reference
Why animal studies are often poor predictors of human reactions to exposure
10.1258/jrsm.2008.08k033 · 2009 · External reference
In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist
10.1007/s00204-018-2201-4 · 2018 · External reference
Lost in translation: animal models and clinical trials in cancer treatment
2014 · External reference
Human organs-on-chips for disease modelling, drug development and personalized medicine
10.1038/s41576-022-00466-9 · 2022 · External reference
When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis
10.1371/journal.pone.0147215 · 2016 · External reference
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
10.1038/nrd.2017.244 · 2018 · External reference
Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development
10.14573/altex.2001241 · 2020 · External reference
Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications
10.1039/c9lc01168d · 2020 · External reference
Reconstituting organ-level lung functions on a chip
10.1126/science.1188302 · 2010 · External reference
A multi-organ chip with matured tissue niches linked by vascular flow
10.1038/s41551-022-00882-6 · 2022 · External reference
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
10.1039/c8lc00322j · 2018 · External reference
Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development
10.1038/psp.2013.41 · 2013 · External reference
Physiologically based pharmacokinetics joined with in Vitro–In vivo extrapolation of ADME: a marriage under the arch of systems pharmacology
10.1038/clpt.2012.65 · 2012 · External reference
PBPK modeling and simulation in drug research and development
10.1016/j.apsb.2016.04.004 · 2016 · External reference
Unresolved reference
2011 · External reference
A six-stage workflow for robust application of systems pharmacology
10.1002/psp4.12071 · 2016 · External reference
Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked organs-on-chips
10.1146/annurev-pharmtox-010716-104748 · 2018 · External reference
Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips
10.1038/s41551-019-0498-9 · 2020 · External reference
Generative artificial intelligence empowers digital twins in drug discovery and clinical trials
10.1080/17460441.2023.2273839 · 2024 · External reference
A modular computational framework for medical digital twins
10.1073/pnas.2024287118 · 2021 · External reference
Virtual patients, digital twins and causal disease models: paving the ground for in silico clinical trials
10.1016/j.drudis.2023.103605 · 2023 · External reference
PBPK modeling on organs-on-chips: an overview of recent advancements
10.3389/fbioe.2022.900481 · 2022 · External reference
Microphysiological systems as reliable drug discovery and evaluation tools: evolution from innovation to maturity
10.1063/5.0179444 · 2023 · External reference
Organ-on-a-chip meets artificial intelligence in drug evaluation
10.7150/thno.87266 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry
10.1039/c9lc00768g · 2020 · External reference
The current status and use of microphysiological systems by the pharmaceutical industry: the international consortium for innovation and quality microphysiological systems affiliate survey and commentary
10.1124/dmd.123.001510 · 2024 · External reference
Concordance of the toxicity of pharmaceuticals in humans and in animals
10.1006/rtph.2000.1399 · 2000 · External reference
A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model
10.1007/s00204-014-1276-9 · 2014 · External reference
Organs-on-chips: progress, challenges, and future directions
10.1177/1535370217700523 · 2017 · External reference
Microphysiological systems: stakeholder challenges to adoption in drug development
10.1159/000517422 · 2021 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Machine learning chained neural network analysis of oxygen transport amplifies the physiological relevance of vascularized microphysiological systems
10.1002/btm2.10582 · 2023 · External reference
A computer vision approach for analyzing label free leukocyte trafficking dynamics on a microvascular mimetic
10.3389/fimmu.2023.1140395 · 2023 · External reference
CPHNet: a novel pipeline for anti-HAPE drug screening via deep learning-based cell painting scoring
10.1186/s12931-025-03173-1 · 2025 · External reference
Development of an in vitro assessment method for chemotherapy-induced peripheral neuropathy (CIPN) by integrating a microphysiological system (MPS) with morphological deep learning of soma and axonal images
10.3390/toxics11100848 · 2023 · External reference
Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system
10.1124/jpet.116.237495 · 2017 · External reference
Translational assessment of drug-induced proximal tubule injury using a kidney microphysiological system
10.1002/psp4.12400 · 2019 · External reference
A pharmacokinetic-pharmacodynamic model based on multi-organ-on-a-chip for drug-drug interaction studies
10.1063/5.0011545 · 2020 · External reference
Prediction of hepatic drug clearance with a human microfluidic four-cell liver acinus microphysiology system
10.1016/j.tox.2021.152954 · 2021 · External reference
